GHP November 2017 - Rejuvenation Dentistry

28 GHP / November 2017 , 1706GH04 Central Hub for New Ideas and Innovation TheMilner Therapeutics Institute was co-founded by Dr JonathanMilner, a benefactor of the research laboratories and Professor Tony Kouzarides who conceived the mission and directs the Institute. The ExecutiveManager is Dr Kathryn Chapman. Here at The Milner Therapeutics Institute, we are integrated into the School of Biological Sciences and School of Clinical Medicine at the University of Cambridge, UK. The aims of our Institute are to: • Connect industry and academia • Enable collaborative research • Accelerate biotech spin-outs These aims are realised through our global therapeutic alliance which consists of: • Affiliate Partners: We connect people with common research interests via a set of affiliated academic institutions, affiliated companies and venture partners. The companies are service and product providers that are developing tools to advance therapeutic needs. The venture partners provide mentoring and potential funding opportunities. The Institute coordinates interactions between affiliated companies and academic, pharmaceutical or biotechnology partners, with the aim of finding collaborative opportunities to make a cohesive therapeutically minded community. • Therapeutics Consortium: We enable collaborative research by lowering the barriers of engagement between academia and industry via the Therapeutics Consortium. The Consortium is a partnership of three Cambridge academic Institutions (the University of Cambridge, the Babraham Institute and the Welcome Trust Sanger Institute) and seven pharmaceutical companies (Astex, AstraZeneca, Elysium, GlaxoSmithKline, Johnson & Johnson Innovation, Pfizer and Shionogi) who have signed an agreement to engage in pre-competitive research in Cambridge. • Research Labs: The laboratories are expected to be operational in late 2018 and will accommodate scientists from affiliated research groups from the Cambridge academic institutes and our pharmaceutical partners. They are expected to house an Innovation Unit with bioinformatics, disease models, and robotics for customised phenotypic drug screening and an Accelerator Unit, which will welcome entrepreneurs to develop ideas for therapeutic companies. The future: Our current focus is to increase the number and success of the collaborative projects that are being conducted under the Milner Therapeutics Consortium agreement, and to assemble the right combination of projects and talent for the Research Labs. The labs will provide a central hub for the Institute and enable the new ideas and innovations to be tested. The eclectic mix of established pharma companies, world-leading academics and budding entrepreneurs working next to each other at the bench will take the Institute to the next level. There are many ways to engage with the Milner Therapeutics Institute through the global alliance. Visit the website (www.milner. cam.ac.uk ) and get in touch via [email protected]. Contact: Kathryn Chapman Contact Email: kathryn. [email protected] Company: The Milner Therapeutics Institute Address: The Milner Therapeutics Institute, University of Cambridge, Cambridge, CB2 1QN, UK Telephone: 01223 767111 Website: www.milner.cam.ac.uk